Myocardial ischaemia in patients with primary APS: A 13 N-ammonia PET assessment

Rheumatology

Volumn 47, Issue 6, 2008, Pages 894-896

  Alexanderson E ^a,b   Gomez Leon A ^a   Vargas, A ^a   Romero, J L ^a   Sierra Fernandez C ^a   Rodriguez Valero, M ^a   Garcia Rojas L ^a   Meave, A ^a   Amigo, M C ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b NONE   (Mexico)

Author keywords

13N ammonia; Autoimmune diseases; Cardiovascular imaging; Coronary disease; Heart; Ischaemia; Ischaemic heart disease; Positron emission tomography; Primary anti phospholipid syndrome; Thrombosis

Indexed keywords

AMMONIA N 13; ANTICOAGULANT AGENT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; EXERCISE TEST; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; MALE; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REST;

ADULT; AMMONIA; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITROGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX;

EID: 44849119472     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken084     Document Type: Article

References (30)

1. Harris EN, Baguley E, Asherson RA et al. Clinical and serological features of the 'antiphospholipid syndrome' (APS) [abstract]. Br J Rheumatol 1987;26:19A.
2. Asherson RA, Khamashta MA, Ordi-Ros J et al. The 'primary' antiphospholipid syndrome: Major clinical and serological features. Medicine 1989;68:366-74.
3. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
4. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-12.
5. Cariou R, Tobelem G, Belluci S et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1988;60:54-8.
6. Greisman SG, Thayaparan R-S, Godwin TA et al. Occlusive vasculopathy in systemic lupus erythematosus: Association with anticardiolipin antibody. Arch Intern Med 1991;151:389-92.
7. Lockshin MD. Antiphospholipid antibody and the antiphospholipid syndrome. Curr Opin Rheumatol 1991;3:797-802.
8. Ames PRJ. Medical perspective. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus. A unifying 'membrane stress syndrome' hypothesis. Lupus 1994;3:371-7.
9. Hansson GK, Libby P, Schonbeck V, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-91.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
11. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-26.
12. Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997; 8:301-11.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26.
14. George J, Harats D, Gilburd B et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 1999;99:2227-30.
15. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: Are they proatherogenic or an epiphenomenona of atherosclerosis? Immunobiology 2003;207:13-6.
16. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995;238:437-43.
17. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erithematosus. Am J Med 1980;69:849-58.
18. Shelbert HR. Principles of positron emission tomography. In: Marcus ML, Shelbert HR, Skorton DJ, Wolf GL, eds. Cardiac imaging. Philadelphia: WB Saunders, 1991:1140-270.
19. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
20. Muzik O, Beanlands RS, Hutchins GD, Manger TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
21. Espinola N, Montes RM, Soto ME, Avila N, Amigo MC. Primary antiphospholipid syndrome: A 5-year transesophageal echocardiographic followup study. J Rheumatol 2004;31:2402-7.
22. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170-5.
23. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-27.
24. Díaz MN, Becker RC. Anticardiolipin antibodies in patients with unstable angina. Cardiology 1994;84:383-4.
25. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7(Suppl. 2):132-4.
26. Espinola-Zavaleta N, Alexanderson E, Granados N, Soto ME, Amigo MC. Myocardial perfusion defects in patients with autoimmune diseases: A prospective study. Analysis of two diagnostic tests. Lupus 2006;15:38-43.
27. Alexanderson E, Cruz P, Sierra C, Talayero JA, Meave A. Cardiopatía isquémica: Evaluación anatomofuncional en una sola exploración con PET-CT multicorte. Arch Cardiol Mex 2006;76(Suppl. 4):111-20.
28. Khamashta M. Anticardiolipin test (Hughes) syndrome: 20 years and counting! [editorial]. J Rheumatol 2004;31:2099-101.
29. Del Río García E, Rodríguez C, Rodríguez-Martorell J et al. Platelet and endothelial activation are requisites for the development of antiphospholipid syndrome. Ann Rheum Dis 2004;63:600-1.
30. Pierangeli S, Vega-Ostertag M, Nigel Harris E. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: A pathway to targeted therapies. Thromb Res 2004;5-6:467-76.